AstraZeneca PLC (ETR:ZEG)
Germany
· Delayed Price · Currency is EUR | Market Cap | 208.44B |
| Revenue (ttm) | 52.23B |
| Net Income (ttm) | 6.80B |
| Shares Out | n/a |
| EPS (ttm) | 4.35 |
| PE Ratio | 30.68 |
| Forward PE | n/a |
| Dividend | 2.93 (2.17%) |
| Ex-Dividend Date | Feb 20, 2025 |
| Volume | 12,369 |
| Average Volume | 38,816 |
| Open | 136.00 |
| Previous Close | 134.90 |
| Day's Range | 136.00 - 136.95 |
| 52-Week Range | 117.30 - 158.20 |
| Beta | 0.16 |
| RSI | 42.44 |
| Earnings Date | Apr 29, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
The Japanese Ministry of Health, Labour and Welfare on Thursday approved BridgeBio Pharma, Inc. ‘s (NASDAQ: BBIO) acoramidis, under the brand name Beyonttra , for adults with transthyretin-mediated a...
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
The Japanese Ministry of Health, Labour and Welfare on Thursday approved BridgeBio Pharma, Inc.‘s BBIO acoramidis, under the brand name Beyonttra, for adults with transthyretin-mediated amyloid cardio...
J&J boasts Rybrevant, Lazcluze combo bests AstraZeneca's Tagrisso
Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC SEOUL, S...
The women behind life-saving Covid vaccine trials
Three women who worked on the Oxford AstraZeneca Covid vaccine talk to the BBC about their work.
AstraZeneca's TAGRISSO Shows Promising Results in Lung Cancer Trials
AstraZeneca's TAGRISSO Shows Promising Results in Lung Cancer Trials
After China probe, is AstraZeneca’s new US$2.5 billion plan a blueprint for foreign firms?
British-Swedish drug maker has gone from Beijing’s scrutiny to its praise, hailed as a sign of doing business in China.
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
The Association of the British Pharmaceutical Industry (ABPI) is urging ministers to address excessive levies on manufacturers to ensure the sector remains competitive globally. The life sciences indu...
AstraZeneca CEO on its $2.5 billion investment in Beijing hub
British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in the Chinese capital.
AstraZeneca to invest $2.5bn in drugs research and manfacturing in Beijing
Pharmaceutical company will invest money over five years in ‘strategic partnership’ with the city’s authorities Business live – latest updates AstraZeneca will invest $2.5bn in research and manufactur...
AstraZeneca to Invest $2.5 Billion in China Amid Probes
The drugmaker plans to build a research-and-development center in Beijing and strike deals with local biotechnology companies, at a time when Chinese authorities are probing it.
Watch CNBC's full interview with AstraZeneca CEO Pascal Soriot
Pascal Soriot, CEO of British pharmaceutical giant AstraZeneca, discusses the company's $2.5 billion investment in a new China research and development center.
Watch CNBC's full interview with Pascal Soriot, AstraZeneca CEO
Pascal Soriot, CEO, AstraZeneca discusses the company's $2.5 billion investment in its new China research and development centre.
Watch CNBC's full interview with AstraZeneca CEO Pascal Soriot on its $2.5 billion China investment
Pascal Soriot, CEO of British pharmaceutical giant AstraZeneca, discusses the company's $2.5 billion investment in a new China research and development center.
AstraZeneca expands in China with a $2.5B investment in Beijing
AstraZeneca to invest $2.5bn in China after scandal
London-listed drugmaker will establish research centre in Beijing
Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies
SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands , March 21, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and comm...
British pharma giant AstraZeneca to invest $2.5 billion in new China hub
British pharmaceutical giantAstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing, China.
AstraZeneca investing $2.5 bln in China as drugmaker seeks to recover from scandals
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including ...
Angle PLC Announces Results of Eisai Phase 2 pilot study
UPDATE ON ASTRAZENECA ASSAY DEVELOPMENT PROJECTS AND SUCCESSFUL COMPLETION OF EISAI CONTRACTDevelopment of both the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay s...
Stock Market Today: Welspun Corp, Nuvama, AstraZeneca, Bharti Airtel, Aavas Financiers hit 52-week highs on March 20, 2025
The stock market witnessed a strong rally in several stocks on March 20, 2025, with Welspun Corp, Nuvama, AstraZeneca, Bharti Airtel, and Aavas Financiers touching their 52-week highs. These stocks sa...
Mindpeak to deploy and evaluate AI-Powered Digital Pathology Risk Assessment Tools for Breast Cancer in collaboration with AstraZeneca
HAMBURG, Germany--(BUSINESS WIRE)--The collaboration aims to assess the transformative potential of AI in digital pathology, with a specific focus on accelerating primary breast cancer diagnosis. Brea...
IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals
CAMBRIDGE, United Kingdom , March 17, 2025 /PRNewswire/ -- IgniteData has announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) and Cambridge University Hospitals NHS Foundation Trust (CUH)...
AstraZeneca to buy cell therapy biotech for up to $1 billion
AstraZeneca will pay $425 million upfront for EsoBiotec and may spend up to $575 million more in development and regulatory milestones, the companies said.
AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details
EsoBiotec SA , a biotechnology company specializing in in vivo cell therapies, has announced a definitive agreement to be acquired by AstraZeneca PLC (NYSE: AZN). The agreement represents a major ste...